Back

Kazia to expand TNBC trial into HR+/HER2- breast cancer by 2026

Verifying
  • Kazia Therapeutics will expand its TNBC trial into HR+/HER2- metastatic breast cancer.
  • First-patient enrollment is expected by end-2026; full enrollment is anticipated by end-2027.
  • Paxalisib combinations produced statistically significant tumor-volume reductions without added toxicity preclinically.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.